☆ 4.1 Article

Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines

REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL (2023)

Related references

Note: Only part of the references are listed.

Article Cell Biology

Age-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose

Bruno Andraus Filardi et al.

Summary: The emergence of the SARS-CoV-2 Omicron sublineages resulted in increased transmission rates and reduced vaccine protection. Homologous CoronaVac booster doses showed lower efficiency in enhancing immune response compared to heterologous BNT162b2 or ChAdOx1 boosters, especially in individuals over 50 years old. These findings emphasize the potential benefits of heterologous vaccination strategies for older adults fully vaccinated with CoronaVac during the Omicron wave.

SCIENCE TRANSLATIONAL MEDICINE (2023)

Add to Collection

Article Medicine, General & Internal

Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint

Xinhua Chen et al.

Summary: The study shows that a homologous third dose of COVID-19 vaccines can provide higher neutralizing antibody levels and better protection against the Delta variant compared to the primary series. Irrespective of vaccine technology, all types of vaccines included in the study are predicted to effectively prevent symptomatic and severe cases of COVID-19 caused by the Delta variant.

BMC MEDICINE (2022)

Add to Collection

Article Virology

Dynamics of antibody response to CoronaVac vaccine

Marcela Helena Gambim Fonseca et al.

Summary: This study evaluated the antibody response to CoronaVac in healthcare workers and found that the antibody levels and seropositivity decreased after 6 months of vaccination. Females had higher antibody levels and there was a positive correlation with previous SARS-CoV-2 infection. Participants with comorbidities had lower antibody levels.

JOURNAL OF MEDICAL VIROLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

Sue Ann Costa Clemens et al.

Summary: A study was conducted to evaluate the safety and immunogenicity of a third dose of heterologous or homologous vaccines in Brazilian adults who had previously received two doses of CoronaVac. The results showed that a third dose of heterologous vaccines (recombinant adenoviral vectored vaccine or mRNA vaccine) significantly increased immune responses and could improve protection against infection.

LANCET (2022)

Add to Collection

Article Medicine, General & Internal

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

Arabella S. Stuart et al.

Summary: The study investigated the mixed use of different COVID-19 vaccines within the same schedule, showing that in certain conditions, heterologous vaccination can achieve similar immunogenicity to homologous vaccination, facilitating rapid global vaccine deployment.

LANCET (2022)

Add to Collection

Article Infectious Diseases

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

Gang Zeng et al.

Summary: The study showed that a two-dose schedule of CoronaVac generated good immune response in adults, and a third dose given 8 months after the second dose effectively recalled specific immune responses to SARS-CoV-2, leading to a remarkable increase in antibody concentration. This indicates that the two-dose schedule provides good immune memory, and a primary third dose given 2 months after the second dose induced slightly higher antibody titres than the primary two doses.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination

Samuel M. S. Cheng et al.

Summary: Specific antibody levels against the SARS-CoV-2 Omicron variant decrease significantly after two doses of BNT162b2 or CoronaVac vaccines, but can be markedly increased with a booster dose of BNT162b2. Individuals who previously received two doses of BNT162b2 or CoronaVac showed reduced serum antibody titers against Omicron, while a BNT162b2 booster dose increased the antibody levels in the majority of individuals. This suggests mRNA vaccine boosters may be necessary in countries primarily using CoronaVac vaccines to combat the spread of Omicron.

NATURE MEDICINE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial

Jingxin Li et al.

Summary: The study suggests that additional COVID-19 vaccine doses may be needed for individuals who initially received CoronaVac. Heterologous boosting with Convidecia, a recombinant adenovirus type 5 (AD5)-vectored vaccine, was found to be safe and more immunogenic than homologous boosting with CoronaVac in adults previously vaccinated with CoronaVac.

NATURE MEDICINE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination

Eddy Perez-Then et al.

Summary: The study found that a BNT162b2 mRNA vaccine booster can enhance neutralizing antibodies against the Omicron variant in individuals who received two doses of the CoronaVac vaccine, but antibody titers remain lower compared to the ancestral virus and the Delta variant.

NATURE MEDICINE (2022)

Add to Collection

Article Respiratory System

Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong

Chris Ka Pun Mok et al.

Summary: The study found that vaccination with BNT162b2 induces significantly stronger humoral immune responses than CoronaVac. Additionally, BNT162b2 vaccine recipients had higher levels of antibody protection threshold. Age was negatively correlated with antibody levels post-vaccination. Both vaccines induced SARS-CoV-2-specific T-cell responses, but CoronaVac elicited higher levels of structural protein-specific T-cell responses.

RESPIROLOGY (2022)

Add to Collection

Article Infectious Diseases

Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study

Denis Saure et al.

Summary: The study in Chile found that individuals who received the CoronaVac vaccine had a lower IgG seropositivity compared to those who received the BNT162b2 vaccine. Over time, the IgG seropositivity for CoronaVac recipients declined, while those who received BNT162b2 maintained high levels of IgG positivity. Further monitoring of IgG levels will help in evaluating vaccine effectiveness and exploring potential adjustments to vaccination strategies in the future.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Virology

The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine

Jessica Pires Farias et al.

Summary: Vaccination can significantly reduce the number of infected individuals, although there is a downward trend in specific antibody levels after vaccination, the use of booster shots with Pfizer can increase specific SARS-CoV-2 IgG serum levels. Vaccination is more effective than natural infection with SARS-CoV-2.

JOURNAL OF VIROLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant

Fanglei Zuo et al.

Summary: This study demonstrates that an mRNA vaccine booster in individuals vaccinated with inactivated vaccines can significantly increase the humoral and cellular immune responses against the virus, including the Omicron variant.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Environmental Sciences

Booster Doses of Anti COVID-19 Vaccines: An Overview of Implementation Policies among OECD and EU Countries

Fabrizio Bert et al.

Summary: This study explored health policies regarding the COVID-19 booster dose through an overview of recommendations issued in high-income countries. The majority of countries started administering the booster dose between September and November 2021, using mRNA vaccines as the most common product. All countries established criteria to define priority populations for vaccination, with varying intervals depending on the vaccine and vulnerable individuals.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2022)

Add to Collection

Article Immunology

Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey

Meliha Cagla Sonmezer et al.

Summary: Vaccines, such as CoronaVac and BNT162b2, have shown effectiveness in preventing symptomatic COVID-19 cases. The third dose of these vaccines can provide further protection against severe COVID-19. It is important to prioritize the administration of third-dose boosters as an effective strategy in combating the pandemic.

VACCINES (2022)

Add to Collection

Letter Infectious Diseases

Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19

Wey Wen Lim et al.

LANCET MICROBE (2021)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Alasdair P S Munro et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

Robert H Shaw et al.

LANCET (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Joana Barros-Martins et al.

Summary: A study found that booster vaccination with BNT162b2 in healthcare professionals previously vaccinated with ChAdOx-1 nCoV-19 elicited more neutralizing antibodies and higher frequencies of virus-specific T cells. Additionally, BNT162b2 induced high titers of neutralizing antibodies against variants of concern, such as B.1.1.7, B.1.351, and P.1.

NATURE MEDICINE (2021)

Add to Collection

Article Immunology

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

Ling Ni et al.

IMMUNITY (2020)

Add to Collection

© Peeref 2019-2024. All rights reserved.